

MOSAIC ZIMBABWE CATALYST STUDY STAGE 2 NEWS

24 April 2024



Cabotegravir, a long-acting injectable form of Pre-Exposure Prophylaxis (PrEP)

 **Breaking News: MOSAIC CATALYST Study Advances HIV Prevention with Stage 2 Rollout!** 



In a groundbreaking move, Pangaea Zimbabwe in collaboration with the Ministry of Health and Child Care (MoHCC), has officially launched the MOSAIC CATALYST Study-stage 2 at the SHAZ! Hub clinic in Chitungwiza, marking a pivotal moment in HIV prevention strategies and in promoting **#HIVPreventionchoice**.




This exciting development represents a breakthrough in HIV prevention, offering individuals a new era of choice in their prevention journey and empowerment for individuals at risk of HIV infection. With the addition of the injectable CAB, we now have three effective biomedical options for HIV prevention:



From the established efficacy of oral PrEP to the discreet protection of the Ring, and now the revolutionary injectable CAB, individuals have greater agency than ever before in safeguarding their health.

This momentous occasion not only underscores the relentless pursuit of innovation in the field of HIV prevention but also reaffirms our commitment to providing diverse and accessible solutions for all.



The aim is to deliver **PrEP choice** across multiple PrEP products for women. This expansion of options empowers individuals to choose the prevention method that best suit their lifestyle and needs. As we forge ahead, let us unite in the shared mission of eradicating HIV by promoting **#HIVPreventionCHOICE**.